Harpoon, Aligos announce PIPEs; NAYA's all-stock deal; Invea to go public
Harpoon’s $150M PIPE: Harpoon Therapeutics announced a private placement that is expected to raise a total of $150 million a month after AbbVie opted out of an exclusive option for its BCMA-targeting T cell engager in multiple myeloma. The biotech did not disclose the lead investor, though it noted that its investors include Soleus Capital, Commodore Capital and New Leaf Venture Partners, among others. Its stock $HARP was down about 8% on Monday morning after the PIPE was announced.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.